mTORC1/2 Inhibition Re-Sensitizes Platinum-Resistant Ovarian Cancer by Disrupting Selective Translation of DNA Damage and Survival mRNAs

Oncotarget - United States
doi 10.18632/oncotarget.25869
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

PARP Inhibitor Re‑sensitizes Adriamycin Resistant Leukemia Cells Through DNA Damage and Apoptosis

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab

Clinical Medicine Insights: Oncology
Oncology
2019English

Is HIPEC Beneficial in Platinum Resistant Relapsed Ovarian Cancer?

Romanian Journal of Medical Practice
2019English

A Comprehensive Analysis of Radiosensitization Targets; Functional Inhibition of DNA Methyltransferase 3B Radiosensitizes by Disrupting DNA Damage Regulation

Scientific Reports
Multidisciplinary
2015English

EZH2 Inhibition Re-Sensitizes Multidrug Resistant B-Cell Lymphomas to Etoposide Mediated Apoptosis

Oncoscience
Cancer ResearchOncology
2016English

Targeted Treatment of Recurrent Platinum-Resistant Ovarian Cancer: Current and Emerging Therapies

Cancer Management and Research
Oncology
2010English

Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2003English

Reversing Platinum Resistance in Ovarian Cancer Multicellular Spheroids by Targeting BCL-2

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy